



Version **Revision Date:** SDS Number: Date of last issue: 2024/07/06 6097523-00018 8.1 2024/09/28 Date of first issue: 2020/06/30

1. PRODUCT AND COMPANY IDENTIFICATION

Chemical product name Ivermectin Formulation

Supplier's company name, address and phone number

Company name of supplier MSD

Address Kumagaya, Saitama Prefecture, Xicheng 810 MSD Co., Ltd.

Menuma factory

Telephone 048-588-8411

E-mail address EHSDATASTEWARD@msd.com

Emergency telephone number : +1-908-423-6000

Recommended use of the chemical and restrictions on use

Recommended use Veterinary product Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

GHS classification of chemical product

single exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system)

repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Central nervous system)

Short-term (acute) aquatic

hazard

Category 1

Long-term (chronic) aquatic

hazard

Category 1

GHS label elements

Hazard pictograms

Signal word Warning

Hazard statements H371 May cause damage to organs (Central nervous system) if

H373 May cause damage to organs (Central nervous system)





Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

through prolonged or repeated exposure if swallowed. H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

Response

P308 + P311 IF exposed or concerned: Call a POISON

CENTER/ doctor. P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	ENCS No.
Ivermectin	70288-86-7	>= 1 - < 2.5	-
2,6-Di-tert-butyl-p-cresol	128-37-0	>= 0.1 - < 1	3-540, 9-1805

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do

so by medical personnel. Get medical attention.

Rinse mouth thoroughly with water.





SDS Number: Date of last issue: 2024/07/06 Version Revision Date: 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and

delayed

Protection of first-aiders

May cause damage to organs if swallowed.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate contain-





SDS Number: Date of last issue: 2024/07/06 Version Revision Date: 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

> ment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Use only with adequate ventilation. Do not breathe mist or vapours. Advice on safe handling

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact

Oxidizing agents

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Storage

Conditions for safe storage Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

> Oxidizing solids Oxidizing liquids

Unsuitable material: None known. Packaging material





Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Threshold limit value and permissible exposure limits for each component in the work environment

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Concentration standard / Permissible concentration	Basis	
Ivermectin	70288-86-7	TWA	30 μg/m3 (OEB 3)	Internal	
	Further information: Skin				
		Wipe limit	300 µg/100 cm2	Internal	
2,6-Di-tert-butyl-p-cresol	128-37-0	8h-OEL-M	10 mg/m3	JP ISHL OEL 577-2(2)	
		TWA (Inhal- able fraction and vapor)	2 mg/m3	ACGIH	

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices).

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially



Ivermectin Formulation

Version 8.1

Revision Date: 2024/09/28

SDS Number: 6097523-00018

Date of last issue: 2024/07/06 Date of first issue: 2020/06/30

contaminated clothing.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state oily

Colour light yellow

Odour characteristic

Odour Threshold No data available

Melting point/freezing point No data available

Boiling point, initial boiling

point and boiling range

167.5 °C

Flammability (solid, gas) Not applicable

Flammability (liquids) No data available

Lower explosion limit and upper explosion limit / flammability limit

Upper explosion limit / Up- : No data available

per flammability limit

Lower explosion limit /

Lower flammability limit

No data available

Flash point 219.2 °C

Decomposition temperature No data available

pΗ No data available

No data available Evaporation rate

Auto-ignition temperature No data available

Viscosity

Viscosity, kinematic No data available

Solubility(ies)

Water solubility practically insoluble

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure No data available

Density and / or relative density

Relative density 0.88 - 0.92



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Density : No data available

Relative vapour density : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : Not applicable

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition

products

Oxidizing agentsNo hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

Ivermectin:

Acute oral toxicity : LD50 (Rat): 50 mg/kg

LD50 (Mouse): 25 mg/kg

LD50 (Monkey): > 24 mg/kg



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

> Target Organs: Central nervous system Symptoms: Vomiting, Dilatation of the pupil Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg

LD50 (Rat): > 660 mg/kg

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit

Result : No skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Ivermectin:

Species : Rabbit

Result : Mild eye irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Ivermectin:

Exposure routes : Dermal Species : Humans

Result : Does not cause skin sensitisation.

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Species : Humans Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ivermectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: human diploid fibroblasts

Result: negative

Test Type: Mouse Lymphoma

Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Ivermectin:

Species : Rat Application Route : Oral

NOAEL : 1.5 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

Species : Mouse Application Route : Oral

NOAEL : 2.0 mg/kg body weight

Result : negative

Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Ivermectin:

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Oral

Fertility: NOAEL: 0.6 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Mouse Application Route: Oral

Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

Test Type: Development

Species: Rat



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Application Route: Oral

Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected.

Remarks: The mechanism or mode of action may not be rele-

vant in humans.

Test Type: Development

Species: Rabbit Application Route: Oral

Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally

toxic doses

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

Components:

Ivermectin:

Target Organs : Central nervous system
Assessment : Causes damage to organs.

STOT - repeated exposure

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

Components:

Ivermectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Repeated dose toxicity

Components:

Ivermectin:

Species : Dog
NOAEL : 0.5 mg/kg
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Target Organs : Central nervous system

Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey
NOAEL : 1.2 mg/kg
Application Route : Oral
Exposure time : 2 Weeks

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 0.4 mg/kg

LOAEL : 0.8 mg/kg

Application Route : Oral

Exposure time : 3 Months

Target Organs : spleen, Bone marrow, Kidney

2,6-Di-tert-butyl-p-cresol:

Species : Rat
NOAEL : 25 mg/kg
Application Route : Ingestion
Exposure time : 22 Months

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ivermectin:

Skin contact : Remarks: Can be absorbed through skin.

Eye contact : Remarks: May irritate eyes.

Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vom-

iting, anorexia, Lack of coordination





Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ivermectin:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l

Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.000025 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

M-Factor (Chronic aquatic

toxicity)

10,000

10,000

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

Exposure time: 96 h

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

1



Ivermectin Formulation

Version SDS Number: Date of last issue: 2024/07/06 **Revision Date:** 6097523-00018 8.1 2024/09/28 Date of first issue: 2020/06/30

Toxicity to fish (Chronic tox-

icity)

NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l

NOEC (Daphnia magna (Water flea)): 0.316 mg/l

Exposure time: 30 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

Exposure time: 21 d

ic toxicity)

: 1

M-Factor (Chronic aquatic toxicity)

Toxicity to microorganisms

EC50: > 10,000 mg/l Exposure time: 3 h

Method: OECD Test Guideline 209

Persistence and degradability

Components:

Ivermectin:

Result: Not readily biodegradable. Biodegradability

> Biodegradation: 50 % Exposure time: 240 d

2,6-Di-tert-butyl-p-cresol:

Biodegradability Result: Not readily biodegradable.

Biodegradation: 4.5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

Bioaccumulative potential

Components:

Ivermectin:

Bioaccumulation Bioconcentration factor (BCF): 74

Partition coefficient: n-

octanol/water

log Pow: 3.22

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-

octanol/water

log Pow: 5.1

Mobility in soil No data available

Hazardous to the ozone layer

Not applicable





Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 964

aircraft)

Packing instruction (passen:

: 964

ger aircraft)

Environmentally hazardous : yes

....

IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

National Regulations

Refer to section 15 for specific national regulation.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

ERG Code : 171

15. REGULATORY INFORMATION

Related Regulations

Fire Service Law

Group 4, Type 4 petroleums, (6000 litre), Hazardous rank III

Chemical Substance Control Law

Priority Assessment Chemical Substance

Chemical name	Number
2,6-Di-tert-butyl-4-methylphenol	64

Industrial Safety and Health Law

Harmful Substances Prohibited from Manufacture

Not applicable

Harmful Substances Required Permission for Manufacture

Not applicable

Substances Prevented From Impairment of Health

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 2: Information on Existing Chemicals having Mutagenicity

Not applicable

Circular concerning Information on Chemicals having Mutagenicity - Annex 1: Information on Notified Substances having Mutagenicity

Not applicable

Substances Subject to be Notified Names

Article 57-2 (Enforcement Order Table 9)

Chemical name	Concentration (%)	Remarks
2,6-Di-tert-butyl-4-cresol	>=0.1 - <1	-

Substances Subject to be Indicated Names

Not applicable

Skin and Eye Damage Substances for PPE Requirements (ISHL MO Art. 594-2)

Not applicable



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

Carcinogenic Substances (Article 577-2 of the Occupational Health and Safety Regulations)

Not applicable

Ordinance on Prevention of Hazards Due to Specified Chemical Substances

Not applicable

Ordinance on Prevention of Lead Poisoning

Not applicable

Ordinance on Prevention of Tetraalkyl Lead Poisoning

Not applicable

Ordinance on Prevention of Organic Solvent Poisoning

Not applicable

Enforcement Order of the Industrial Safety and Health Law - Attached table 1 (Dangerous Substances)

Not applicable

Poisonous and Deleterious Substances Control Law

Not applicable

Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the Environment and Promotion of Improvements to the Management Thereof

Not applicable

High Pressure Gas Safety Act

Not applicable

Explosive Control Law

Not applicable

Vessel Safety Law

Miscellaneous dangerous substances and articles (Article 2 and 3 of rules on shipping and storage of dangerous goods and its Attached Table 1)

Aviation Law

Miscellaneous dangerous substances and articles (Article 194 of The Enforcement Rules of Aviation Law and its Attached Table 1)

Marine Pollution and Sea Disaster Prevention etc Law

Bulk transportation : Not classified as noxious liquid substance

Pack transportation : Classified as marine pollutant

Narcotics and Psychotropics Control Act

Narcotic or Psychotropic Raw Material (Export / Import Permission)

Not applicable

Specific Narcotic or Psychotropic Raw Material (Export / Import permission)

Not applicable

Waste Disposal and Public Cleansing Law

Industrial waste

The components of this product are reported in the following inventories:



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

In this SDS, if the concentration of substances subject to notification under the Industrial Safety and Health Law is indicated as a range, it includes cases where it is a trade secret.

Further information

Sources of key data used to

compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

JP ISHL OEL 577-2(2) : Concentration standard (Value set by the Minister of Health,

Labour and Welfare stipulated under the Ministerial Ordinance

Article 577-2(2))

ACGIH / TWA : 8-hour, time-weighted average

JP ISHL OEL 577-2(2) / 8h- : 8-hour Occupational Exposure Limit-Mean

OEL-M

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No



Ivermectin Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/07/06 8.1 2024/09/28 6097523-00018 Date of first issue: 2020/06/30

1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

JP / EN